NASDAQ: SRZN - Surrozen, Inc.

Доходность за полгода: -0.1025%
Дивидендная доходность: 0.00%
Сектор: Healthcare

График акции Surrozen, Inc.


О компании Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

подробнее
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

IPO date 2021-01-11
ISIN US86889P1093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 10.66
Изменение цены за день: +2.74% (9.49)
Изменение цены за неделю: +3.17% (9.45)
Изменение цены за месяц: -15.95% (11.5999)
Изменение цены за 3 месяца: -17.72% (11.85)
Изменение цены за полгода: -0.1025% (9.76)
Изменение цены за год: +4.17% (9.36)
Изменение цены за 3 года: +223.92% (3.01)
Изменение цены с начала года: -7.71% (10.565)

Недооценка

Название Значение Оценка
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Итого: 6.13

Эффективность

Название Значение Оценка
ROA, % -93.41 0
ROE, % -113.46 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -0.0822 10
Итого: 9.8

Импульс роста

Название Значение Оценка
Доходность Revenue, % 0 0
Доходность Ebitda, % 80.4 9
Доходность EPS, % 416.44 10
Итого: 7.2



Руководитель Должность Оплата Год рождения
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 года)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 лет)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 лет)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 лет)
Esther Jhun Controller N/A

Адрес: United States, South San Francisco. CA, 171 Oyster Point Boulevard - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.surrozen.com